Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Shares of Pfizer Inc. PFE shed 3.49% to $21.84 Tuesday, on what proved to be an all-around poor trading session for the stock ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends.

and stock price implications if they prove true. If Pfizer withheld material information from regulators or investors for political or market timing, it may face action from the Securities and ...

the PFE stock reacted like a rocket; when it became clear that COVID was gone, Pfizer gave back over 56% of its market cap. Now that the firm is showing the first signs of EBITDA stabilization and ...

Prevnar 20 retained an 87% market share in the US, with pediatric sales holding two-thirds of revenues. Pfizer’s COVID-19 portfolio has stable utilization trends ... we have no stock, option ...